(R)-2-(2-chloro-5-iodopyrimidin-4-ylamino)propan-1-ol | 942410-79-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (R)-2-(2-chloro-5-iodopyrimidin-4-ylamino)propan-1-ol
• 英文别名: (R)-2-(2-chloro-5-iodopyrimidine-4-ylamino)propan-1-ol；(2R)-2-[(2-chloro-5-iodopyrimidin-4-yl)amino]propan-1-ol
• CAS: 942410-79-9
• 化学式: C₇H₉ClIN₃O
• 分子量: 313.525
• InChiKey: SKYXKQMSUXJMEP-SCSAIBSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  58
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-2-(2-chloro-5-iodopyrimidin-4-ylamino)propan-1-ol 、 ethyl [(3-aminophenyl)(methyl)oxido-λ⁶-sulphanylidene]carbamate 在 盐酸 、 sodium ethanolate 作用下， 以 1,4-二氧六环 、 乙醇 、 水 、 乙腈 为溶剂， 反应 0.5h， 生成 (RS)-S-(3-{[4-{(R)-2-(hydroxy-1-methylethyl)amino}-5-iodopyrimidin-2-yl]amino}phenyl)-S-methylsulfoximide
  参考文献：
  名称：

  WO2008/155140

  摘要：

  公开号：
• 作为产物：
  描述：

  D-氨基丙醇 、 2,4-二氯-5-碘嘧啶 以the desired product is obtained in 88% yield (1.6 g)的产率得到(R)-2-(2-chloro-5-iodopyrimidin-4-ylamino)propan-1-ol
  参考文献：
  名称：

  Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs

  摘要：

  该发明涉及通式I的亚砜基取代的嘧啶化合物的制备方法及其作为药物的用途。

  公开号：

  US20070232632A1

文献信息

• Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same and uses of the same
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP1878726A1

  公开（公告）日：2008-01-16

  The invention relates to substituted sulphoximines according to the general formula (I): in which A, E, G, X, R1, R2, R3, R4, R5, R6, R7, R8, m, p, q, are given in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted sulphoximines, to methods of preparing said substituted sulphoximines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.

  该发明涉及通式（I）所示的取代磺酰羟肟化合物，其中A、E、G、X、R1、R2、R3、R4、R5、R6、R7、R8、m、p、q在权利要求中给出，以及其盐，包括所述取代磺酰羟肟化合物的药物组合物，制备所述取代磺酰羟肟化合物的方法以及将其用于制造用于治疗血管生长失调疾病或伴随血管生长失调的疾病的药物组合物，其中这些化合物有效干扰Tie2信号传导。
• SUBSTITUTED SULPHOXIMINES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME
  申请人：Hartung Ingo

  公开号：US20080064696A1

  公开（公告）日：2008-03-13

  The invention relates to substituted sulphoximines according to the general formula (I): in which A, E, G, X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , m, p, q, are given in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted sulphoximines, to methods of preparing said substituted sulphoximines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.

  本发明涉及通式（I）的取代磺酰肟化合物，其中A、E、G、X、R1、R2、R3、R4、R5、R6、R7、R8、m、p、q在权利要求书中给出，以及其盐，制备该取代磺酰肟化合物的方法，以及将其用于制造用于治疗失调血管生长疾病或伴随失调血管生长的疾病的药物组合物，其中该化合物有效地干扰Tie2信号传导。
• ALKYNYLPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME
  申请人：Hartung Ingo

  公开号：US20090099219A1

  公开（公告）日：2009-04-16

  The invention relates to alkynylpyrimidines according to the general formula (I): in which A, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are as defined in the claims, and salts, N-oxides, metabolites, solvates, tautomers and prodrugs thereof, to pharmaceutical compositions comprising said alkynylpyrimidines, to methods of preparing said alkynylpyrimidines, as well as to uses thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 and VEGFR2 signalling.

  本发明涉及一种按照通式（I）定义的炔基嘧啶化合物，其中A、R1、R2、R3、R4、R5和R6如权利要求所定义的，并且其盐、N-氧化物、代谢物、溶剂合物、互变异构体和前药，以及包含该炔基嘧啶化合物的制药组合物，制备该炔基嘧啶化合物的方法，以及用于制备治疗失调血管生长疾病或伴随失调血管生长的疾病的制药组合物的用途，其中该化合物有效干扰Tie2和VEGFR2信号传导。
• Substituted sulphoximines as TIE2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
  申请人：Bayer Schering Pharma AG

  公开号：US08003655B2

  公开（公告）日：2011-08-23

  The invention relates to substituted sulphoximines according to the general formula (I): in which A, E, G, X, R1, R2, R3, R4, R5, R6, R7, R8, m, p, q, are given in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted sulphoximines, to methods of preparing said substituted sulphoximines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.

  本发明涉及通式(I)的替代硫氧亚胺化合物： 其中A、E、G、X、R1、R2、R3、R4、R5、R6、R7、R8、m、p、q在权利要求书中给出，并且其盐，以及包含所述替代硫氧亚胺化合物的制药组合物，制备所述替代硫氧亚胺化合物的方法以及其用于制造用于治疗失调的血管生长或伴随失调的血管生长的疾病的制药组合物的用途，其中所述化合物有效地干扰Tie2信号传递。
• Alkynylpyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
  申请人：Hartung Ingo

  公开号：US08524724B2

  公开（公告）日：2013-09-03

  The invention relates to alkynylpyrimidines according to the general formula (I): in which A, R1, R2, R3, R4, R5, and R6 are as defined in the claims, and salts, N-oxides, metabolites, solvates, tautomers and prodrugs thereof, to pharmaceutical compositions comprising said alkynylpyrimidines, to methods of preparing said alkynylpyrimidines, as well as to uses thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 and VEGFR2 signalling.

  本发明涉及通式（I）的炔基嘧啶化合物： 其中，A，R1，R2，R3，R4，R5和R6如权利要求所定义的那样，以及其盐，N-氧化物，代谢物，溶剂合物，互变异构体和前药。本发明还涉及包含所述炔基嘧啶化合物的制药组合物，制备所述炔基嘧啶化合物的方法，以及将其用于制备用于治疗失调血管生长或伴随失调血管生长的疾病的制药组合物的用途，其中该化合物有效干预Tie2和VEGFR2信号传导。